Pedro Ylisastigui, MD
Internal Medicine · Lehigh Acres, FLNPI 1477610715
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (58.4%), consulting fees and education — rather than concentrated in one kind of arrangement. 12 manufacturers reported payments, led by GSK at 45.5% of the total. Reporting peaked in 2023 at $2,250 and has fallen 89.3% since, to $240 in 2025. Among internal medicine clinicians in FL with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 35 payments — averaging $128.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$2K
- AstraZeneca$1K
- Johnson & Johnson$268
- Novo Nordisk$251
- Boehringer Ingelheim$200
- Boston Scientific$142
- plus $528 from 6 others
Across 896 payments — averaging $8126.01 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- GSK$1.8M
- Johnson & Johnson$833K
- Vertex$815K
- Boehringer Ingelheim$708K
- Pfizer$620K
- Astrazeneca UK Limited$560K
- plus $1.9M from 14 others
What the payments were for
- Consulting fees$1,85641%
- Food & beverage$2,62558%
- Education$120%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 4 | $2,044 |
| AstraZeneca | 11 | $1,061 |
| Johnson & Johnson | 3 | $268 |
| Novo Nordisk | 7 | $251 |
| Boehringer Ingelheim | 2 | $200 |
| Boston Scientific | 1 | $142 |
| Amgen | 1 | $133 |
| Sanofi-aventis U.S. LLC | 1 | $125 |
| Phathom Pharmaceuticals, Inc. | 1 | $120 |
| Lilly USA, LLC | 2 | $101 |
| Merck | 1 | $34 |
| Abbott | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$4,493 in reported general payments places this provider in the 90th percentile of 8,530 internal medicine providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FarxigaDapagliflozin Propanediol | 139 | $181,544 |
| JardianceEmpagliflozin | 92 | $147,336 |
| EliquisApixaban | 78 | $97,408 |
| TradjentaLinagliptin | 91 | $91,309 |
| JanuviaSitagliptin Phosphate | 74 | $76,240 |
| TrulicityDulaglutide | 54 | $61,956 |
| OzempicSemaglutide | 35 | $38,752 |
| Dexlansoprazole DrDexlansoprazole | 62 | $28,358 |
| Diclofenac Sodium | 399 | $26,466 |
| RybelsusSemaglutide | 18 | $25,550 |
| LinzessLinaclotide | 13 | $22,084 |
| JanumetSitagliptin Phos/Metformin Hcl | 24 | $20,815 |
| EntrestoSacubitril/Valsartan | 12 | $19,006 |
| XareltoRivaroxaban | 19 | $16,656 |
| BrilintaTicagrelor | 19 | $15,859 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Tradjenta, Synjardy | $200 | $250,976201 claims |
| AstraZenecaFarxiga, Brilinta | $1,061 | $197,403158 claims |
| MerckJanuvia, Janumet | $34 | $97,05598 claims |
| Novo NordiskOzempic, Rybelsus | $251 | $64,30253 claims |
| Lilly USA, LLCTrulicity | $101 | $61,95654 claims |
| Johnson & JohnsonXarelto | $268 | $16,65619 claims |
| Sanofi-aventis U.S. LLCLantus | $125 | $2,18312 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 8,530 internal medicine providers in Florida.
Other internal medicine in Lehigh Acres
- Haytham ElgammalMiami$2.2M
- Keith RubinFort Lauderdale$2M
- Michael SensionFort Lauderdale$1M
- Quang NguyenOcala$434K
- Luis Correa LunaSanford$412K
- Michael OleksykFort Myers$365K
- Andrew KuykendallTampa$322K
- Howard FederoffCoconut Grove$302K
- Bianka EperjesiovaGainesville$260K
- Julio ConradoFort Myers$247K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.